-
Neuralstem: A Top Regenerative Medicine Play
An ex-scientist and professional investor and analyst provides a forward-looking overview of Neuralstem’s near-term NSI-566 trials, and reports on the company’s NSI-189/MDD Phase Ib trial currently underway.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.